• Viral Infections
• Psoriasis
• Malignancies
  • › Solid Tumors
  • › Angiogenesis
  • › Acute Myeloid Leukemia (AML)
• Neurological Disorders

Home > Applications > Malignancies > Solid Tumors

AS101 exhibited ability to sensitize tumors to various chemotherapy agents like paclitaxel (Taxol), cyclophosphamid (CYP), 5-fluorouracil, doxorubicin, lomustine and VP-16. The anti- tumoral activity of AS101 and its chemotherapy synergistic effect was were studied in various in-vitro and in-vivo models of carcinomas (lewis lung carcinoma, lung adenocarcinoma, stomach adenocarcinoma), melanomas (B16-F10 melanoma cell line injected to the lung of mice), blastomas (Glioblastoma) and Cutaneous T-cell lymphomas (Mycosis fungoides ).

In phase II clinical trial with chemotherapy treated metastatic non-small-cell lung cancer (NSCLC) patients, AS101 showed significant bone marrow (BM) sparing effects, with minimal overall toxicity due to its immunomodulating activities. AS101 significantly reduced neutropenia and thrombocytopenia and thus allowed all treated patients to receive full-dose antineoplastic agents, in contrast to only 28.5% in the control group. Although AS101 was able to spare Chemotherapy- induced BM toxicity, it did not provide protection of tumor cells and higher overall response rate was found in the AS101 treated group.

See relevant publications

For more info
Printable Version

Solid Tumors treatment